Medtronic Management

Management criteria checks 3/4

Medtronic's CEO is Geoff Martha, appointed in Apr 2020, has a tenure of 4.42 years. total yearly compensation is $15.39M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth $4.43M. The average tenure of the management team and the board of directors is 3.3 years and 9.3 years respectively.

Key information

Geoff Martha

Chief executive officer

US$15.4m

Total compensation

CEO salary percentage	8.8%
CEO tenure	4yrs
CEO ownership	0.004%
Management average tenure	3.3yrs
Board average tenure	9.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Geoff Martha's remuneration changed compared to Medtronic's earnings?
Date	Total Compensation	Salary	Company Earnings
Jan 26 2024	n/a	n/a	US$4b
Oct 27 2023	n/a	n/a	US$4b
Jul 28 2023	n/a	n/a	US$4b
Apr 28 2023	US$15m	US$1m	US$4b
Jan 27 2023	n/a	n/a	US$4b
Oct 28 2022	n/a	n/a	US$4b
Jul 29 2022	n/a	n/a	US$5b
Apr 29 2022	n/a	n/a	US$5b
Jan 28 2022	n/a	n/a	US$5b
Oct 29 2021	n/a	n/a	US$5b
Jul 30 2021	n/a	n/a	US$4b
Apr 30 2021	US$18m	US$1m	US$4b
Jan 29 2021	n/a	n/a	US$3b
Oct 30 2020	n/a	n/a	US$4b
Jul 31 2020	n/a	n/a	US$4b
Apr 24 2020	US$6m	US$905k	US$5b
Jan 24 2020	n/a	n/a	US$5b
Oct 25 2019	n/a	n/a	US$5b
Jul 26 2019	n/a	n/a	US$4b
Apr 26 2019	US$4m	US$693k	US$5b

Compensation vs Market: Geoff's total compensation ($USD15.39M) is above average for companies of similar size in the UK market ($USD5.62M).

Compensation vs Earnings: Geoff's compensation has been consistent with company performance over the past year.

CEO

Geoff Martha (53 yo)

4yrs

Tenure

US$15,394,632

Compensation

Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Chairman at Medtron...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Geoffrey Martha	Chairman of the Board & CEO	4yrs	US$15.39m	0.0042% $ 4.4m
Karen Parkhill	Executive VP & CFO	7.8yrs	US$6.12m	0.0050% $ 5.3m
Sean Salmon	Executive VP & President of Cardiovascular Portfolio	no data	US$5.36m	0.0019% $ 2.0m
Robert J. ten Hoedt	Executive VP & President of Global Regions	9.3yrs	US$5.05m	0.0024% $ 2.5m
Mark Ploof	Senior Vice President of Global Operations and Business Services	7.5yrs	no data	no data
Jennifer Kirk	Senior VP	2.8yrs	no data	0.00099% $ 1.0m
Kenneth Washington	Senior VP and Chief Technology & Innovation Officer	less than a year	no data	no data
Laura Mauri	Senior VP and Chief Scientific	2yrs	no data	no data
Ryan Weispfenning	VP & Head of Investor Relations	8.8yrs	no data	no data
Ivan Fong	Executive VP	2.2yrs	US$11.72m	0.00082% $ 868.2k
Torod Neptune	Senior VP & Chief Communications Officer	3.3yrs	no data	no data
Matt Walter	Chief Human Resources Officer	less than a year	no data	no data

3.3yrs

Average Tenure

58yo

Average Age

Experienced Management: 0Y6X's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Geoffrey Martha	Chairman of the Board & CEO	4.4yrs	US$15.39m	0.0042% $ 4.4m
Scott Donnelly	Independent Director	11.3yrs	US$365.01k	0.00099% $ 1.0m
Kendall Powell	Independent Director	17.3yrs	US$350.01k	0.0013% $ 1.4m
Randall Hogan	Independent Director	9.3yrs	US$385.01k	0.0031% $ 3.3m
Craig Arnold	Lead Independent Director	9.3yrs	US$410.01k	0.0026% $ 2.7m
Denise O'Leary	Independent Director	24.3yrs	US$375.01k	0.0028% $ 3.0m
Andrea Goldsmith	Independent Director	5.1yrs	US$370.01k	0.00033% $ 349.4k
Elizabeth Nabel	Independent Director	10.3yrs	US$370.01k	0.00088% $ 931.7k
Lidia Fonseca	Independent Director	1.8yrs	US$294.37k	no data
Kevin Lofton	Independent Director	3.6yrs	US$370.01k	0.00017% $ 180.0k
Gregory Lewis	Independent Director	less than a year	no data	no data

9.3yrs

Average Tenure

63yo

Average Age

Experienced Board: 0Y6X's board of directors are considered experienced (9.3 years average tenure).

Medtronic Management

Management criteria checks 3/4

Key information

Recent management updates

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Recent updates

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Upcoming dividend of US$0.69 per share

Third quarter dividend of US$0.69 announced

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Third quarter 2024 earnings released: EPS: US$0.99 (vs US$0.92 in 3Q 2023)

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Upcoming dividend of US$0.69 per share at 3.5% yield

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: US$0.68 (vs US$0.32 in 2Q 2023)

Now 20% undervalued after recent price drop

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Now 21% undervalued after recent price drop

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Upcoming dividend of US$0.69 per share at 3.4% yield

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

First quarter 2024 earnings released: EPS: US$0.59 (vs US$0.70 in 1Q 2023)

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Upcoming dividend of US$0.69 per share at 3.1% yield

Upcoming dividend of US$0.69 per share at 3.1% yield

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Upcoming dividend of US$0.68 per share at 3.5% yield

Third quarter 2023 earnings released: EPS: US$0.92 (vs US$1.10 in 3Q 2022)

Medtronic plc to Report Q3, 2024 Results on Feb 20, 2024

Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Medtronic Announces First Patient Enrolled in U.S. Clinical Trial for Hugo™ Robotic-Assisted Surgery System

Upcoming dividend of US$0.68 per share

Medtronic plc Approves Cash Dividend for the Third Quarter of Fiscal Year 2023, Payable on January 13, 2023

Medtronic Completes Enrollment in Pivotal Trial Evaluating First-Of-Its-Kind Pulsed Field Ablation Catheter for Patients with Atrial Fibrillation

Second quarter 2023 earnings released: EPS: US$0.32 (vs US$0.97 in 2Q 2022)

Medtronic plc Provides Revenue Results for the Second Half of 2023

Medtronic's SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with Other SPYRAL HTN Renal Denervation Trials

Medtronic plc Launches of Medtronic Neurovascular Co-Lab Platform to Accelerate Innovation in Stroke Treatment

dorsaVi Partners with Medtronic to Develop New Technology

Medtronic plc Introduces New Program Called My Insights Exclusively Made for Individuals Using MiniMed™ 770G System

Medtronic plc to Receive FDA Approval for Pacing the Heart's Natural Conduction System

Now 21% undervalued after recent price drop

Medtronic plc Receives FDA Clearance for Expanded Indication of LINQ II™ Insertable Cardiac Monitor for Use in Pediatric Patients Ages 2 and Older

Medtronic plc Announces SYMPLICITY HTN-3 Trial Data Show Sustained Long-Term Blood Pressure Reductions with Medtronic Renal Denervation Procedure

Upcoming dividend of US$0.68 per share

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Medtronic plc

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age